Canine
Update (June 17, 2026): Scoping Review Maps Metabolic and Gut-Brain Alterations in Canine Idiopathic Epilepsy — Emerging Adjunct Targets
TL;DR
A 2026 scoping review identifies consistent alterations in metabolic, immune, and gut-brain axis pathways in dogs with idiopathic epilepsy, positioning canine epilepsy as a translational model for human disease and pointing to dietary and microbiome-based approaches as emerging adjunct targets alongside established antiseizure medications.
What just dropped
- Cabri et al. 2026 (Nutrients 18(11):1734, published May 28 2026; DOI 10.3390/nu18111734; PMID 42280378; open access): PRISMA-ScR scoping review of original studies reporting metabolic, immunometabolic, or neurochemical alterations in canine idiopathic epilepsy (CE) compared with healthy controls (Web of Science + MEDLINE search). Eligible studies used IVETF (International Veterinary Epilepsy Task Force) consensus criteria for CE diagnosis.
- Consistent alterations observed across CE studies included amino acid and lipid metabolism, micronutrients, neurotransmission, oxidative stress, inflammation, endocannabinoid signalling, microRNAs, and gut-brain axis pathways -- paralleling findings in human epilepsy.
- Translational implications noted by the authors include dietary and metabolic approaches (for example, medium-chain triglyceride supplementation), microbiome modulation, and immunometabolic targeting as mechanism-based intervention candidates.
- Current evidence is limited by small and heterogeneous cohorts, potential confounding effects of antiseizure medications, variability in dietary and fasting conditions, breed-related effects, and predominance of associative over causal relationships.
Context
The Cabri 2026 review does not provide clinical trial data on antiseizure medication efficacy. Its value is in establishing a research framework for systemic, non-CNS contributors to seizure threshold in dogs -- a perspective increasingly relevant as metabolic and microbiome-targeted interventions are explored in human epilepsy research.
Separately, a retrospective analysis of primary care practices in the US (Pompermaier et al. 2026, Front Vet Sci 13:1723038; PMID 41737686) documented that potassium bromide serum concentrations were monitored in only 31.6% of dogs receiving KBr, compared with 77.5% monitoring for phenobarbital. This TDM gap provides practical context for clinicians choosing between antiseizure drug classes: established agents like KBr and phenobarbital have well-characterised biochemical monitoring parameters, whereas emerging adjunct metabolic targets described in the Cabri review are not yet supported by TDM frameworks.
What this changes in potassium-bromide-dogs-idiopathic-epilepsy (https://www.thevoyage.ai/forvets/knowledge/potassium-bromide-dogs-idiopathic-epilepsy)
The Cabri 2026 scoping review does not alter the evidence base for potassium bromide as a primary or adjunctive antiseizure agent in dogs, but adds relevant context around the expanding metabolic research landscape. Clinicians should continue prioritising established TDM (serum bromide monitoring) for KBr-treated patients -- the Pompermaier 2026 data showing only 31.6% monitoring compliance is a practical reminder of the monitoring gap -- while remaining aware that metabolic and dietary adjunct data are emerging.
References
- Cabri G, Bhatti SFM, Hemeryck LY, et al. Canine Idiopathic Epilepsy as a Natural Animal Model for Human Epilepsy: A Scoping Review Highlighting Metabolic Perspectives Beyond the Brain. Nutrients. 2026 May 28;18(11):1734. DOI: 10.3390/nu18111734 (https://doi.org/10.3390/nu18111734)
- Pompermaier E, Morrison JA, Stabile F, De Risio L. Retrospective study on canine idiopathic epilepsy treatment in primary care practices in the United States. Front Vet Sci. 2026;13:1723038. DOI: 10.3389/fvets.2026.1723038 (https://doi.org/10.3389/fvets.2026.1723038)
Related reads
References
More clinical updates
Update (June 17, 2026): Adjunctive FMT Reduces Lesion Severity and Medication Use in Canine Atopic Dermatitis — First RCT
A June 2026 double-blinded RCT (40 dogs) found adjunctive faecal microbiota transplantation reduced CADESI-04 scores and medication requirements in cAD versus placebo.
Read →Update (June 17, 2026): Lymph Food RCT Improves Lesion Scores and Reduces Medication Use in Dogs with Atopic Dermatitis
Frizzo-Ramos 2025 (112-day RCT, 38 dogs): lymph food supplement added to standard cAD care reduced CADESI-4 by 55% vs +26% placebo (p<0.0003) and cut medication use.
Read →Update (June 17, 2026): Bedinvetmab Plus Physiotherapy Outperforms Bedinvetmab Alone on Pain Threshold in Dogs With Hip OA
Cidral 2026 RCT (30 dogs): bedinvetmab + photobiomodulation/PEMF superior to bedinvetmab alone on algometry from Day 30 (p=0.027), more pronounced at D60-90 (p<0.001).
Read →Update (June 17, 2026): Survey of 373 Vets Finds Wide Canine OA Practice Variation — Bedinvetmab Paresis/Ataxia Signal at 31%
Bird 2026 survey (373 vets): NSAIDs dominate canine OA Rx; bedinvetmab perceived neurological AEs at 31%; grapiprant GI AEs (diarrhea 33%, vomiting 31%) most reported.
Read →